You are here:Home-Research Areas-Neurological Disease-Anxiety

Request The Product List ofAnxiety Anxiety

Cat. No. Product Name CAS No. Information
PC-43382

WAY-100635 maleate

634908-75-1 WAY-100635 is a potent and selective 5-HT1A receptor antagonist; also acts as potent full agonist at the D4 receptor; completely prevents not only the hyperpolarization, with an IC50 of 1.3 nM, but also the decrease in membrane input resistance produced by 5-HT and 5-carboxamidotryptamine with IC50 of 22.5 μM and 50 nM, respectively.

Anxiety

Phase 1 Discontinued

PC-62769

TPA023

252977-51-8 TPA023 is a potent, α2/α3 subtype-selective, and oral GABAA receptor agonist with Kd of 0.92, 1.05 and 0.58 nM for α1-, α2-, α3-, and α5-containing human receptors; shows much lower (50- to 2000-fold) affinities for α4 and α6 subtypes (Ki= 60 and 418 nM, respectively); demonstrates anxiolytic-like efficacy and anticonvulsant activity in mouse pentylenetetrazole seizure model.

Anxiety

Discontinued

PC-62765

AZD6280

942436-93-3 AZD6280 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 7.7; exerts neutral antagonism at the α1-subunit and partial efficacy at the α2,3-subunits over the α5-subunit, shows potential for the treatment of anxiety disorders.

Anxiety

Phase 1 Discontinued

PC-62760

SB 206553

1197334-04-5 SB 206553 is a potent and selective 5-HT2B/5-HT2C receptor antagonist with pA2 of 8.89 for rat 5-HT2B, pKi of 7.92 for human 5-HT2C, displays >80-fold selectivity over other 5-HT receptor subtypes; exhibits anxiolytic-like properties both in vitro and in vivo.

Anxiety

Discontinued

PC-62533

SSR 411298

666860-59-9 SSR411298 is a highly selective, brain penetrant and orally-active inhibitor of FAAH with IC50 of 62.5 nM (mouse brain FAAH); potently increases hippocampal levels of AEA, OEA and PEA in mice, produces robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress models.

Anxiety

Phase 1 Clinical

PC-62090

AZD-7325

942437-37-8 AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51; exerts neutral antagonism at the α1-subunit and partial efficacy at the α2,3-subunits over the α5-subunit; AZD7325 is expected to reduce the risk for the benzodiazepine like side effects, such as sedation and cognitive effects, and shows potential for the treatment of anxiety.

Anxiety

Phase 1 Clinical

PC-61834

Imagabalin hydrochloride

610300-00-0 Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2; demonstrated preclinical efficacy of anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity for the treatment of generalized anxiety disorder.

Anxiety

Phase 3 Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com